To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04675710
Title Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Stanford School of Medicine Stanford California 94304 United States Details
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 United States Details
Mayo Clinic Rochester Minnesota 55901 United States Details
Cleveland Clinic Taussig Cancer Institute Cleveland Ohio 44195 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
Huntsman Cancer Institute at the University of Utah Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field